Form 4: Replimune Director Joseph Slattery Awarded 44,500 Options

Director Joseph P. Slattery received 44,500 stock options with an exercise price of $7.61, scheduled to vest in April 2027.

Summary

• Joseph P. Slattery, a director at Replimune Group, Inc., was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share.
• The grant is scheduled to vest in its entirety on April 1, 2027.
• The options have a ten-year term, expiring on April 1, 2036.
• The disclosure was submitted late due to an administrative error.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event as it confirms director alignment, though the late filing is a minor administrative negative.

Positives

• Aligns director interests with shareholder value through equity-based compensation.
• The exercise price of $7.61 establishes a clear baseline for future growth expectations.
• Long-term commitment is evidenced by the ten-year expiration window.

Negatives

• The disclosure was filed late, which represents a minor regulatory compliance oversight.
• Future exercise of these options will result in a minor dilution of existing shares.

Risks

• Administrative errors in reporting can occasionally indicate underlying weaknesses in internal reporting controls.

Future Outlook

The one-year cliff vesting schedule suggests a focus on director retention and mid-term corporate performance through 2027.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice in the biotechnology sector to align board oversight with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size of 44,500 options is consistent with director compensation packages at mid-cap biotech firms like Amgen or Gilead.
• A one-year full vesting period is a common structure for annual director equity awards in the NASDAQ Biotechnology Index.

Corporate Governance

Related Party Transactions

• Issuance of derivative securities to a member of the Board of Directors as part of compensation.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.
• The board's stability is supported by the vesting requirement.

Next Steps

• Full vesting of the options on April 1, 2027.

Key Dates

Recommendation

This is a routine administrative filing regarding director compensation and does not provide new material information regarding the company's clinical pipeline or financial health.

Keywords

Replimune Group, REPL, Insider Trading, Stock Options, Joseph Slattery, Director Compensation, Biotechnology